People · Operator
Named in public records as an officer, director or promoter · active 2009–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lux Biosciences Inc | — | Biotechnology | Series B | $81.1M | $635.0M | 2009 |
| Noveome Biotherapeutics, Inc. | — | Biotechnology | Series B | $54.8M | $382.2M | 2015 |
A. Clarke Atwell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside A. Clarke Atwell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| David Guyer | 1 | 8 |
| David Schnell | 1 | 7 |
| MICHAEL KAUFMAN | 1 | 7 |
| Axel Bolte | 1 | 6 |
| Eric Keller | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Thomas Dyrberg | 1 | 5 |
| Craig Nemiroff | 1 | 4 |
| Houman Hemmati | 1 | 4 |
| Donald Wagner | 1 | 3 |
| Paul G. Chaney | 1 | 2 |
| Dean J. Mitchell | 1 | 2 |
| William Golden | 1 | 2 |
| Ulrich M. Grau | 1 | 1 |
| David Clarke Schnell | 1 | 1 |
| Brett Skolnik | 1 | 1 |
| Eddy Anglade | 1 | 1 |
| Paul Clarke Chaney | 1 | 1 |
| Axel Clarke Bolte | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.